Combined double CK5/P63 stain: Useful adjunct test for diagnosing pulmonary squamous cell carcinoma

Increasing demand for accurate differentiation of pulmonary squamous cell carcinoma (SQCC) from other subtypes can be challenging for pathologists. This is more so in fine‐needle aspirations (FNA) since the sample is small and SQCC may show degenerative changes and necrosis that distort the cellular features. Immunohistochemistry (IHC) is a valuable adjunct, and CK5/6 and P63 immunoreactivity is found to be basically restricted to SQCC. In our study, we evaluated the efficiency of CK5/P63 double staining in the diagnosis of pulmonary SQCC in cell blocks (CB) of lung FNA. We used a cohort including 24 CB of lung SQCC and 34 CB of lung adenocarcinomas (ADC). IHC was performed for CK5/P63 double stain. Seventeen of 24 (70%) lung SQCC were positive for the double stain CK5/P63. Two (8%) were positive for CK5 alone and two (8%) were positive for P63 alone. Thus, a total 19 of 24(79%) SQCC of the lung were positive for CK5 and P63 each. In ADC, no immunoreactivity was detected for CK5 alone or combined CK5/P63. Three of 34(8%) ADC were positive for P63. This first study of double staining of CK5/P63 in FNA CB shows a sensitivity of 70% and specificity of 100% for SQCC of the lung. When each marker staining alone is included, the sensitivity for CK5 and P63 increases to 79% each. This double stain can help in the diagnosis of pulmonary SQCC with an accuracy of 88% and a positive predictive value of 100%. Diagn. Cytopathol. 2012. © 2011 Wiley Periodicals, Inc.

[1]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  A. Calvo,et al.  Improving the accuracy of FNA lung biopsies in a community hospital. , 2010 .

[3]  V. Rusch,et al.  Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  H. Benjamin,et al.  Accurate Classification of Non–Small Cell Lung Carcinoma Using a Novel MicroRNA-Based Approach , 2010, Clinical Cancer Research.

[5]  J. Austin,et al.  The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification , 2009 .

[6]  D. Ross,et al.  A novel five-antibody immunohistochemical test for subclassification of lung carcinoma , 2009, Modern Pathology.

[7]  G. Scagliotti,et al.  Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung , 2009, Modern Pathology.

[8]  C. D. Savci-Heijink,et al.  The role of desmoglein-3 in the diagnosis of squamous cell carcinoma of the lung. , 2009, The American journal of pathology.

[9]  Gideon Rechavi,et al.  Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Bo Jian,et al.  Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine‐needle aspiration specimens , 2009, Diagnostic cytopathology.

[11]  G. Scagliotti,et al.  The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. , 2009, The oncologist.

[12]  Anna Spreafico,et al.  The Prognostic and Predictive Role of Histology in Advanced Non-small Cell Lung Cancer: A Literature Review , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  N. Sunaga,et al.  Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I–III nonsmall cell lung cancer , 2008, British Journal of Cancer.

[15]  Richard Pazdur,et al.  FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. , 2007, The oncologist.

[16]  Tammy F. Glenn,et al.  Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration , 2007, International journal of cancer.

[17]  M. Paesmans,et al.  Bevacizumab for non-small-cell lung cancer. , 2007, The New England journal of medicine.

[18]  D. Goldenberg,et al.  Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers , 2007, BMC Cancer.

[19]  D. Burstein,et al.  Cytology applications of p63 and TTF‐1 immunostaining in differential diagnosis of lung cancers , 2005, Diagnostic cytopathology.

[20]  N. Kohno,et al.  Polymorphism of the MUC1 mucin gene is associated with susceptibility to lung adenocarcinoma and poor prognosis. , 2005, Oncology reports.

[21]  D. Burstein,et al.  p63 immunostaining in destained bronchoscopic cytological specimens , 2005, Diagnostic cytopathology.

[22]  D. Burstein,et al.  p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. , 2003, American journal of clinical pathology.

[23]  D. Burstein,et al.  P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. , 2002, Human pathology.

[24]  U. Pastorino,et al.  p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? , 2002, The Journal of pathology.

[25]  R. Strausberg,et al.  A preliminary transcriptome map of non-small cell lung cancer. , 2002, Cancer research.

[26]  M Dietel,et al.  Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. , 2001, American journal of clinical pathology.

[27]  W. Kaelin,et al.  p53 family update: p73 and p63 develop their own identities. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[28]  A. Leong,et al.  Manual of Diagnostic Antibodies for Immunohistology , 1998 .

[29]  D. Zander,et al.  Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach , 2005, Modern Pathology.